Aura Biosciences Q3 net loss widens as R&D costs rise

Aura Biosciences

13/11/2025 12:11

Overview

Aura Biosciences reports Q3 net loss of $26.1 mln, up from $21.0 mln last year

R&D expenses rise to $22.2 mln due to ongoing clinical trials

Outlook

Aura expects Phase 3 CoMpass trial enrollment completion in 2026

Topline data for CoMpass trial expected in Q4 2027

Phase 1b/2 trial data for NMIBC expected mid-2026

Result Drivers

ENROLLMENT CHALLENGES - CoMpass trial enrollment faced delays due to requirement for active tumor growth and operational challenges, now improved

R&D EXPENSES - Increased due to ongoing clinical trials and personnel growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$26.13 mln
Q3 Operating Expenses
$27.91 mln
Q3 Operating Income
-$27.91 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aura Biosciences Inc is $21.00, about 73.5% above its November 12 closing price of $5.57

Press Release: ID:nGNX2Ws1Nw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)